Regulatory Accord, Intas, and Bio-Thera File Four IPRs Against Janssen Golimumab Patents Big Molecule WatchOn March 20, 2026, Accord BioPharma, Inc.RegulatoryImmunology & InflammationRead full story pharminent March 27, 2026 (Last updated: March 30, 2026) Big Molecule Watch On March 20, 2026, Accord BioPharma, Inc. RegulatoryImmunology & InflammationRead full story Post navigation Previous: Otsuka picks up PTSD drug with $700M Transcend buyNext: S16 Ep38: Live Tumor Board: Precision Pathways Transforming Patient Care in Advanced NSCLC Related Stories Regulatory Third Circuit Affirms Denial of Stelara Biosimilar Injunction pharminent May 11, 2026 Regulatory Partner’s Bizengri cleared by FDA for ultra-rare cancer days after winning priority voucher pharminent May 11, 2026 Regulatory BMS’ Sotyktu secures EC approval for psoriatic arthritis pharminent May 11, 2026
